The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Cited by (1,019)

Items 401–500 of 1,019

1. Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms
   Annette K. Brenner, Ina Nepstad, Øystein Bruserud · 2017 · Frontiers in Immunology
2. Myelofibrosis biology and contemporary management
   Naseema Gangat, Ayalew Tefferi · 2020 · British Journal of Haematology
3. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy
   Bhagirathbhai Dholaria, Bipin N. Savani, Betty K. Hamilton, Betül Oran, Hien D. Liu, Martin S. Tallman, Stefan Octavian Ciurea, Noa G. Holtzman, Gordon L. Phillips, Steven Michael Devine et al. · 2020 · Transplantation and Cellular Therapy
4. The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
   Débora Bifano Pimenta, Vanessa Araújo Varela, Tarcila Santos Datoguia, Victória Bulcão Caraciolo, Gabriel Herculano Lopes, Welbert Oliveira Pereira · 2021 · Frontiers in Cell and Developmental Biology
5. Guiding the global evolution of cytogenetic testing for hematologic malignancies
   Yassmine M. N. Akkari, Linda Banovic Baughn, Adrian M. Dubuc, Adam C. Smith, Mar Mallo, Paola Dal Cin, María Díez‐Campelo, Marta Susana Gallego, Isabel Granada, Detlef Thomas Haase et al. · 2022 · Blood
6. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia
   Jayastu Senapati, Elias Joseph Jabbour, Hagop M. Kantarjian, Nicholas James Short · 2022 · Leukemia
7. Myelodysplastic syndromes
   Huan Li, Fang Hu, Robert Peter Gale, Mikkael Aaron Sekeres, Yang Liang · 2022 · Nature Reviews Disease Primers
8. Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
   Craddock, Charles F., Houlton, Aimee E., Quek, Lynn Swun, Ferguson, Paul, Gbandi, Emma, Roberts, Corran, Metzner, Marlen, Garcia-Martin, Natalia, Kennedy, Alison, Hamblin, Angela et al. · 2017 · Clinical Cancer Research
9. Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications
   Lorena Arranz, María del Mar Arriero, Alicia Villatoro · 2017 · Blood Reviews
10. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features
    Giacomo Coltro, Giada Rotunno, Lara Mannelli, Carmela Mannarelli, Sara Fiaccabrino, Simone Romagnoli, Niccolò Bartalucci, Enrica Ravenda, Eleonora Gelli, Emanuela Sant’Antonio et al. · 2020 · Blood Advances
11. Chronic myeloid leukemia stem cells: targeting therapeutic implications
    Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei · 2021 · Stem Cell Research & Therapy
12. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML
    Gabrielle Paras, Linde M. Morsink, Megan K. D. Othus, Filippo Milano, Brenda M. Sandmaier, Lucas C. Zarling, Raffaele Palmieri, Gary H. Schoch, Chris Davis, Marie Bleakley et al. · 2022 · Blood
13. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML
    Jiaxiong Tan, Zhi Hui Yu, Jingying Huang, Youchun Chen, Shuxin Huang, Danlin Yao, Ling Xu, Yuhong Lu, Shaohua Chen, Yangqiu Li · 2020 · Biomarker Research
14. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
    Claude Gardin, Cécile Pautas, Élise Fournier, Raphaël Itzykson, Émilie Lemasle, Jean-Henri Bourhis, Lionel Adès, Jean‐Pierre Marolleau, Jean‐Valère Malfuson, Lauris Gastaud et al. · 2020 · Blood Advances
15. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients
    Kamel Laribi, Alix Baugier de Materre, Mohamad Sobh, Lorenzo Cerroni, Caterina Giovanna Valentini, Tomohiro Aoki, Ritsuro Suzuki, Kengo Takeuchi, Arthur Edward Frankel, Carlo Cota et al. · 2020 · Blood Advances
16. Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia
    Derek H. Janssens, Michael P. Meers, Steven J. Wu, Ekaterina Babaeva, Soheil Meshinchi, Jay F. Sarthy, Kami Ahmad, Steven Henikoff · 2021 · Nature Genetics
17. Prognostic impact ofDDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
    Nicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, Rathana Kim, Julie Rieunier, Juliette Lambert, Audrey Bidet, Lise Larcher, Jean Lemoine, François Delhommeau et al. · 2022 · Blood
18. Polycythemia Vera
    Jerry L. Spivak · 2018 · Current Treatment Options in Oncology
19. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients
    Mohamed-Yacine Khitri, Alexis F. Guédon, Sophie Georgin‐Lavialle, Benjamin Terrier, David Saadoun, Julie Seguier, Maelle le Besnerais, Claire DE MOREUIL, Guillaume Denis, Mathieu Gerfaud‐Valentin et al. · 2022 · RMD Open
20. Molecular taxonomy of myelodysplastic syndromes and its clinical implications
    Elsa Bernard, Robert Paul Hasserjian, Peter L. Greenberg, Juan Arango Ossa, Maria Creignou, Heinz Tuechler, Jesús Gutiérrez‐Abril, Dylan Domenico, Juan Santiago Medina-Martinez, Max Fine Levine et al. · 2024 · Blood
21. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report
    Antonella Caivano, Francesco La Rocca, Vittorio Simeon, M. Girasole, Simone Dinarelli, Ilaria Laurenzana, Angelo De Stradis, Luciana De Luca, Stefania Trino, Antonio Traficante et al. · 2016 · Cellular Oncology
22. Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants
    V Pastor, Shinsuke Hirabayashi, Axel Karow, Julius Wehrle, Emilia J. Kozyra, Ronny Nienhold, Gunda Ruzaike, Dirk Lebrecht, Ayami Yoshimi, Marena Rebekka Niewisch et al. · 2016 · Leukemia
23. Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts
    Peter Valent, Guntram Büsche, Igor Theurl, Iris Z. Uras, Ulrich Germing, Reinhard Stauder, Karl Sotlar, Wolfgang Füreder, Peter Bettelheim, Michael Pfeilstöcker et al. · 2018 · Haematologica
24. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
    Justin Taylor, Stanley Chun-Wei Lee · 2019 · Genes Chromosomes and Cancer
25. Long Non-coding RNAs in Myeloid Malignancies
    Alina‐Andreea Zimța, Ciprian Tomuleasa, Iman Sahnoune, George Adrian Calin, Ioana Berindan‐Neagoe · 2019 · Frontiers in Oncology
26. Brown LM, Lonsdale A, Zhu A, et al. The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia. Blood Adv. 2020;4(5):930-942.
    Lauren M. Brown, Andrew Lonsdale, Andrea Zhu, N. Davidson, Breon Schmidt, Anthony D. K. Hawkins, Elise Wallach, Michelle Martin, Francoise Marie Mechinaud, Seong Lin Khaw et al. · 2020 · Blood Advances
27. Artificial intelligence–based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients
    Korsuk Sirinukunwattana, Alan Aberdeen, Helen Theissen, Nikolaos Sousos, Bethan Psaila, Adam J. Mead, Gareth D. H. Turner, Gabrielle Rees, Jens Rittscher, Daniel J. Royston · 2020 · Blood Advances
28. Azacytidine Treatment for VEXAS Syndrome
    Marc H. G. P. Raaijmakers, Maud Hermans, Anna Aalbers, Melissa Rijken, Virgil A. S. H. Dalm, Paul van Daele, Peter J. M. Valk · 2021 · HemaSphere
29. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms
    Peng Li, Sara Brown, Margaret Williams, Thomas White, Wei Xie, Wei Cui, Deniz Peker, Li Lei, Christian A. Kunder, Huan‐You Wang et al. · 2022 · Blood
30. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM
    Marie Robin, Raphaël Porcher, Lionel Adès, Emmanuel Raffoux, Mauricette Michallet, Sylvie François, Jean-Yves Y. Cahn, Alain Jacques Delmer, Eric Wattel, S. Vigouroux et al. · 2015 · Leukemia
31. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
    Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Kim-Hien T. Dao, Emily A. Stevens, Christopher A. Eide, Vishesh Khanna, Angela Rofelty, Samantha L. Savage, Anna Reister Schultz et al. · 2019 · Blood
32. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
    Lukas Ronner, Nikolai Alexandrovich Podoltsev, Jason R. Gotlib, Mark Lawrence Heaney, Andrew Tucker Kuykendall, Casey Lee O'Connell, Jamile M. Shammo, Angela G. Fleischman, Robyn Marie Scherber, Ruben A. Mesa et al. · 2020 · Blood
33. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map
    Rory Michael Shallis, Rong Wang, Amy J. Davidoff, Xiaomei Ma, Nikolai Alexandrovich Podoltsev, Amer Methqal Zeidan · 2020 · Blood Reviews
34. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
    Amer Methqal Zeidan, Mikkael Aaron Sekeres, Guillermo Garcia‐Manero, David P. Steensma, Katrina Zell, John Barnard, Najla E. Al Ali, Cassie Zimmerman, Gail J. Roboz, Amy Elizabeth Dezern et al. · 2015 · Leukemia
35. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
    Hans Michael Kvasnicka, Jürgen Thiele, Carlos Bueso-Ramos, William Y. Sun, Jörge E. Cortes, Hagop M. Kantarjian, Srđan Verstovšek · 2018 · Journal of Hematology & Oncology
36. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
    Rashmi Kanagal‐Shamanna, Sanam Loghavi, Courtney Denton Dinardo, Leonard Jeffrey Medeiros, Guillermo Garcia‐Manero, Elias Joseph Jabbour, Mark J. Routbort, Rajyalakshmi Luthra, Carlos Bueso-Ramos, Joseph David Khoury · 2017 · Haematologica
37. How I treat polycythemia vera
    Jerry L. Spivak · 2019 · Blood
38. Update on mutations in the HIF: EPO pathway and their role in erythrocytosis
    Terence R.J. Lappin, Frank S. Lee · 2019 · Blood Reviews
39. Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine
    Kiyomi Morita, Nitin Jain, Hagop M. Kantarjian, Koichi Takahashi, Hong Fang, Marina Y Konopleva, Siba El Hussein, Feng Wang, Nicholas James Short, Abhishek Maiti et al. · 2021 · American Journal of Hematology
40. Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia
    John Paul Leonard, Peter Martin, Gail J. Roboz · 2017 · Journal of Clinical Oncology
41. Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models
    Animesh Dev Pardanani, Sahrish H Shah, Francesco Mannelli, Yoseph C. Elala, Paola Guglielmelli, Terra L. Lasho, Mrinal M. Patnaik, Naseema Gangat, Rhett P. Ketterling, Kaaren K. Reichard et al. · 2018 · Blood Advances
42. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia
    Hassan K. Awada, Arda Durmaz, Carmelo Gurnari, Ashwin Kishtagari, Manja Meggendorfer, Cassandra M Kerr, Teodora Kuzmanovic, Jibran Durrani, Jacob Tyler Shreve, Yasunobu Nagata et al. · 2021 · Blood
43. The International Consensus Classification of acute myeloid leukemia
    Olga K. Weinberg, Anna Porwit‐MacDonald, Attilio Orazi, Robert Paul Hasserjian, Kathryn K. Foucar, Eric J. Duncavage, Daniel A. Arber · 2022 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
44. How I treat essential thrombocythemia
    Elisa Rumi, Mario Cazzola · 2016 · Blood
45. Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
    Chi Young Ok, Sanam Loghavi, Dawen Sui, Peng Wei, Rashmi Kanagal‐Shamanna, C. Cameron Yin, Zhuang Zuo, Mark J. Routbort, Guilin Tang, Zhenya Tang et al. · 2018 · Haematologica
46. NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse
    Alexander Höllein, Manja Meggendorfer, Frank Dicker, Sabine Jeromin, Niroshan Nadarajah, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach · 2018 · Blood Advances
47. ETV6-related thrombocytopenia and leukemia predisposition
    Jorge Di Paola, Christopher C. Porter · 2019 · Blood
48. Germline risk of clonal haematopoiesis
    Alexander J. Silver, Alexander G. Bick, Michael Robert Savona · 2021 · Nature Reviews Genetics
49. Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium
    Swantje Buchmann, Martin Schrappe, André Baruchel, Andrea Biondi, Michael J. Borowitz, Myriam Campbell, Gunnar Cario, Giovanni Cazzaniga, Gabriele Escherich, Christine J. Harrison et al. · 2021 · Blood
50. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears
    Jan‐Niklas Eckardt, Tim Schmittmann, Sebastian Riechert, Michael Krämer, Anas Shekh Sulaiman, Katja Sockel, Frank Kroschinsky, Johannes Schetelig, Lisa Wagenführ, Ulrich S. Schuler et al. · 2022 · BMC Cancer
51. Emerging technologies for salivaomics in cancer detection
    Karolina Elżbieta Kaczor‐Urbanowicz, Carmen Martín Carreras‐Presas, Tadeusz Kaczor, Michael Kai Tu, Wei Fang, Franklin Garcı́a-Godoy, David T. Wong · 2016 · Journal of Cellular and Molecular Medicine
52. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status
    Kubesova, B, Pavlova, S, Malcikova, J, Kabathova, J, Radova, L, Tom, N, Tichy, B, Plevova, K, Kantorova, B, Fiedorova, K et al. · 2018 · Leukemia
53. Gene expression and risk of leukemic transformation in myelodysplasia
    Yusuke Shiozawa, Luca Malcovati, Anna Gallì, Andrea Pellagatti, Mohsen Karimi, Aiko Sato‐Otsubo, Yusuke Sato, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida et al. · 2017 · Blood
54. Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions
    A. Chan, C. Chen · 2019 · Front. Cell Dev. Biol.
55. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis ( RARS ‐ T ): 2017 update on diagnosis, risk‐stratification, and management
    Mrinal M. Patnaik, Ayalew Tefferi · 2017 · American Journal of Hematology
56. High-throughput sequencing for noninvasive disease detection in hematologic malignancies
    Florian Scherer, David Matthew Kurtz, Maximilian Diehn, Ash A. Alizadeh · 2017 · Blood
57. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
    Mrinal M. Patnaik, Michael Timm, Rangit Reddy Vallapureddy, Terra L. Lasho, Rhett P. Ketterling, Naseema Gangat, Min Shi, Ayalew Tefferi, Éric Solary, Kaaren K. Reichard et al. · 2017 · Blood Cancer Journal
58. Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC)
    Fady M. Mikhail, Jaclyn A. Biegel, Linda D. Cooley, Adrian M. Dubuc, Betsy A Hirsch, Vanessa L. Horner, Scott Newman, Lina Shao, Daynna J. Wolff, Gordana Raca · 2019 · Genetics in Medicine
59. Pyoderma gangrenosum in hematologic malignancies: A systematic review
    Carmen M. Montagnon, Elizabeth A. Fracica, Archna A. Patel, Michael Camilleri, Mohammad Hassan Murad, David Dingli, David A. Wetter, Stanislav Nickolaevich Tolkachjov · 2019 · Journal of the American Academy of Dermatology
60. The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects
    Bruno Fattizzo, Jessica Rosa, Juri Alessandro Giannotta, Luca Baldini, Nicola Fracchiolla · 2020 · Frontiers in Oncology
61. Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
    Shivam Rai, Élodie Grockowiak, Nils Hansen, Damien Luque Paz, Cédric B. Stoll, Hui Hao-Shen, Gabriele Mild-Schneider, Stefan Dirnhofer, Christopher J. Farady, Simón Méndez‐Ferrer et al. · 2022 · Nature Communications
62. Role ofASXL1andTP53mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
    Raynier Devillier, Véronique Mansat‐De Mas, Véronique Gelsi‐Boyer, Cécile Demur, Anne Murati, Jill Corre, Thomas Prébet, Sarah Bertoli, Mandy Brecqueville, Christine Arnoulet et al. · 2015 · Oncotarget
63. Integrating cancer genomic data into electronic health records
    Jeremy Lyle Warner, Sandeep Kumar Jain, Mia Alyce Levy · 2016 · Genome Medicine
64. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita
    Francesca Fioredda, Simona Iacobelli, Elisabeth T Korthof, Cora Knol, Anja van Biezen, Dorine Bresters, Paul A. Veys, Ayami Yoshimi, Franca Fagioli, Brune Mats et al. · 2018 · British Journal of Haematology
65. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia
    Julia Turbiner Geyer, Wayne Tam, Yen-Chun Liu, Zhengming Chen, Sa A. Wang, Carlos Bueso-Ramos, Jean S. Oak, Daniel A. Arber, Eric D. Hsi, Heesun Joyce Rogers et al. · 2017 · Modern Pathology
66. Turning the tide in myelodysplastic/myeloproliferative neoplasms
    Michael W. Deininger, Jeffrey W Tyner, Éric Solary · 2017 · Nature reviews. Cancer
67. Myelodysplastic Syndrome Updated
    Robert Paul Hasserjian · 2018 · Pathobiology
68. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review
    Jean‐Christophe Ianotto, Natalia Curto‐García, Marie Lauermannová, Deepti H. Radia, Jean‐Jacques Kiladjian, Claire N. Harrison · 2019 · Haematologica
69. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia
    Sophie Ottema, Roger Mulet‐Lazaro, H. Berna Beverloo, Claudia A. J. Erpelinck-Verschueren, Stanley van Herk, Robert M. van der Helm, Marije Havermans, Tim Grob, Peter J.M. Valk, Eric M. Bindels et al. · 2020 · Blood
70. Chronic Myeloid Leukemia in 2020
    Rüdiger Hehlmann · 2020 · HemaSphere
71. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)
    Nicola Polverelli, Katya A. L. Mauff, Nicolaus Martin Kröger, Marie Robin, Dietrich Wilhelm Beelen, David Beauvais, Patrice Chevallier, Mohamad Mohty, Jakob Robert Passweg, Marie‐Thérèse Rubio et al. · 2020 · American Journal of Hematology
72. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
    Damien Luque Paz, Jérémie Riou, Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Jean‐Christophe Ianotto, Brigitte Dupriez, Françoise Boyer, Maxime Renard, Olivier Mansier et al. · 2021 · Blood Advances
73. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
    Valeria Santini, B Allione, Gina Zini, Daniela Maria Gioia, Monia Lunghi, Antonella Poloni, Daniela Cilloni, Alessandro Sanna, Elisa Masiera, M Ceccarelli et al. · 2017 · Leukemia
74. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia
    Mårina Lafage‐Pochitaloff, Laurence Baranger, Mathilde Hunault, Wendy Cuccuini, Christine Lefebvre, Audrey Bidet, Isabelle Tigaud, Virginie Éclache, Éric Delabesse, Chrystèle Bilhou‐Nabera et al. · 2017 · Blood
75. Improving combination cancer therapy: the CombiPlex ® development platform
    Anthony W. Tolcher, Lawrence D. Mayer · 2018 · Future Oncology
76. Venous thromboembolic events during warm autoimmune hemolytic anemia
    Sylvain Audia, Benoit Bach, Maxime Samson, Daniela Lakomy, Jean‐Baptiste Bour, Bénédicte Burlet, Julien Guy, Laurence Duvillard, Marine Branger, Vanessa Leguy Seguin et al. · 2018 · PLoS ONE
77. Targeted next generation sequencing and identification of risk factors in W orld H ealth O rganization defined atypical chronic myeloid leukemia
    Mrinal M. Patnaik, Daniela Barraco, Terra L. Lasho, Christy M. Finke, Kaaren K. Reichard, Katherine P. Hoversten, Rhett P. Ketterling, Naseema Gangat, Ayalew Tefferi · 2017 · American Journal of Hematology
78. RUNX1 Mutations in Inherited and Sporadic Leukemia
    Dana C. Bellissimo, Nancy A. Speck · 2017 · Frontiers in Cell and Developmental Biology
79. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
    Andrea Kuendgen, Meritxell Nomdedéu, Heinz Tuechler, Guillermo Garcia‐Manero, Rami S. Komrokji, Mikkael Aaron Sekeres, Matteo Giovanni Della Porta, Mario Cazzola, Amy Elizabeth Dezern, Gail J. Roboz et al. · 2020 · Leukemia
80. Clonal hematopoiesis driven by chromosome 1q/MDM4 trisomy defines a canonical route toward leukemia in Fanconi anemia
    Marie Sébert, Stéphanie Gachet, Thierry M Leblanc, Alix Rousseau, Olivier Bluteau, Rathana Kim, Raouf Ben Abdelali, Flore Sicre de Fontbrune, Loïc Maillard, Carèle Fédronie et al. · 2023 · Cell stem cell
81. Current Management of Childhood Acute Myeloid Leukemia
    Jeffrey E. Rubnitz · 2016 · Pediatric Drugs
82. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
    Emanuela Sant’Antonio, Paola Guglielmelli, Lisa Pieri, Massimo Primignani, Maria Luigia Randi, Claudia Santarossa, Elisa Rumi, Francisco Cervantes, Federica Delaini, Alessandra Carobbio et al. · 2019 · American Journal of Hematology
83. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia
    Ganqian Zhu, Huacheng Luo, Yang Feng, Olga A. Guryanova, Jianfeng Xu, Chen Shi, Qian Lai, Arati K. Sharma, Bing Xu, Zhigang Zhao et al. · 2021 · Nature Communications
84. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome
    Sa A. Wang, Robert Paul Hasserjian, Wayne Tam, Albert G. Tsai, Julia Turbiner Geyer, Tracy I. George, Kathryn K. Foucar, Heesun Joyce Rogers, Eric D. Hsi, Bryan A. Rea et al. · 2017 · Haematologica
85. MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia
    Pau Montesinos, Benjamin M. Beckermann, Olivier Catalani, Jordi Esteve, Katia Gamel, Marina Y Konopleva, Giovanni Martinelli, Annabelle Monnet, Cristina Papayannidis, Aaron Park et al. · 2020 · Future Oncology
86. IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia
    Tian Yi Zhang, Ritika Dutta, Brooks A. Benard, Feifei Zhao, Raymond R. Yin, Ravindra Majeti · 2020 · Science Translational Medicine
87. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia
    Giovanni Martinelli, Cristina Papayannidis, Alfonso Piciocchi, Valentina Robustelli, Simona Soverini, Carolina Terragna, Giovanni Marconi, Roberto Massimo Lemoli, Fabio Guolo, Antonella Fornaro et al. · 2021 · Blood Advances
88. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
    Amer Methqal Zeidan, Kiyoshi Ando, Odile Beyne‐Rauzy, Mehmet Turgut, Ming‐Chung Wang, Roberto Cairoli, Hsin‐An Hou, Yok‐Lam Kwong, Montserrat Arnán, Stef Meers et al. · 2023 · The Lancet Haematology
89. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice
    C. Ustun, Michel Arock, Hanneke C. Kluin‐Nelemans, Allon Reiter, Wolfgang R. Sperr, Tracy I. George, Hans Peter Horny, Karin Hartmann, Karl Sotlar, Gandhi Laurent Damaj et al. · 2016 · Haematologica
90. Myelofibrosis in 2019: moving beyond JAK2 inhibition
    Michael Schieber, John D. Crispino, Brady Lee Stein · 2019 · Blood Cancer Journal
91. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
    Hsin‐An Hou, Hwei‐Fang Tien · 2020 · Journal of Biomedical Science
92. Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA ‐positive myeloid neoplasm with eosinophilia: Data from 151 patients
    Julien Rohmer, Amélie Couteau‐Chardon, Julie Trichereau, Kewin Panel, Cyrielle Gesquiere, Raouf Ben Abdelali, Audrey Bidet, Jean‐Sébastien Blade, Jean‐Michel Cayuela, Pascale Cony‐Makhoul et al. · 2020 · American Journal of Hematology
93. RASopathies: From germline mutations to somatic and multigenic diseases
    Quentin Riller, Frédéric Rieux‐Laucat · 2021 · Biomedical Journal
94. A longitudinal single-cell atlas of treatment response in pediatric AML.
    S. Lambo, D. Trinh, R. Ries, Dan Jin, A. Setiadi, Michelle Ng, V. LeBlanc, M. Loken, L. Brodersen, Fangyan Dai et al. · 2023 · Cancer Cell
95. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System
    Matteo Giovanni Della Porta, Christopher H. Jackson, Emilio Paolo Alessandrino, Marianna Rossi, Andrea Paolo Bacigalupo, Maria Teresa Van Lint, Massimo Bernardi, B Allione, Alberto Bosi, S. Guidi et al. · 2017 · Leukemia
96. Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
    Derek McCulloch, Christina M. Brown, Harry J. Iland · 2017 · OncoTargets and Therapy
97. Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML
    Dorothée Selimoglu‐Buet, Bouchra Badaoui, Emmanuel Benayoun, Andréa Toma, Pierre Fenaux, Bruno Quesnel, Gabriel Étienne, Thorsten Braun, Nasséra Abermil, Margot Morabito et al. · 2017 · Blood
98. The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know
    Daniel A. Arber · 2018 · Seminars in Hematology
99. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
    Rangit Reddy Vallapureddy, Mythri Mudireddy, Domenico Penna, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Kebede H. Begna, Naseema Gangat, Animesh Dev Pardanani et al. · 2019 · Blood Cancer Journal
100. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome
     Huai-Hsuan Huang, Fei Chen, Wen-Chien Chou, H. Hou, B. Ko, Chien-Ting Lin, Jih-Luh Tang, C. Li, M. Yao, W. Tsay et al. · 2019 · BMC Cancer